First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy

A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news